Business
ImprimisRx to Focus on Investments in Quality at the 2019 American Academy of Ophthalmology Meeting
SAN DIEGO, Oct. 08, 2019 (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business,
About this update from Harrow, Inc.
[{"type":"text","content":"SAN DIEGO, Oct. 08, 2019 (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced its participation at the upcoming 2019 American Academy of Ophthalmology (AAO) Annual Meeting to be held at the Moscone Center in San Francisco, CA, October 12-15. The American Academy of Ophthalmology is the world’s largest association of eye physicians and surgeons, encompassing a community of 32,000 medical doctors. More than 90 percent of practicing ophthalmologists are AAO members. The annual meeting includes a global community of innovators in the art and science of ophthalmology in addition to game-changing research, techniques, and technologies.\n\n \n \n \n \n \n \n \n \n \n \n \n ImprimisRx Logo\n \n \n \n \n \n \n \n \n\n As part of ImprimisRx’s commitment to quality manufacturing, the company will be discussing its ongoing investments in cGMP (Current Good Manufacturing Practices). cGMP standards (21 C.F.R. Parts 210 and 211) are the highest federal drug manufacturing standards. As an FDA-registered and FDA-inspected outsourcing facility, ImprimisRx has made and continues to make significant investments in equipment, processes and personnel to comply with these standards. ImprimisRx’s cGMP compliance program is designed to ensure ImprimisRx’s status as the leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business in the United States. Please click here to view a video discussing cGMP quality processes undertaken to date in ImprimisRx’s manufacturing facilities. John Saharek, President of ImprimisRx, commented, “The need for our formulations has never been greater. With nearly 3.5 million sterile doses dispensed to date and over 6,000 ophthalmic healthcare professionals prescribing our formulations, we see demand continuing to grow as we expand our unique suite of offerings. This year has been a record-breaker and 2020 is likely going be another year of record-breaking growth. Producing products at the highest federal quality standards in our facilities, which are all inspected by the US Food and Drug Administration (FDA), is what our customers expect; and it is what they will get as we ensure access to affordable medications for individuals with needs ...